Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
JCI Insight ; 7(22)2022 11 22.
Article in English | MEDLINE | ID: mdl-36509292

ABSTRACT

Progressive fibrosis and maladaptive organ repair result in significant morbidity and millions of premature deaths annually. Senescent cells accumulate with aging and after injury and are implicated in organ fibrosis, but the mechanisms by which senescence influences repair are poorly understood. Using 2 murine models of injury and repair, we show that obstructive injury generated senescent epithelia, which persisted after resolution of the original injury, promoted ongoing fibrosis, and impeded adaptive repair. Depletion of senescent cells with ABT-263 reduced fibrosis in reversed ureteric obstruction and after renal ischemia/reperfusion injury. We validated these findings in humans, showing that senescence and fibrosis persisted after relieved renal obstruction. We next characterized senescent epithelia in murine renal injury using single-cell RNA-Seq. We extended our classification to human kidney and liver disease and identified conserved profibrotic proteins, which we validated in vitro and in human disease. We demonstrated that increased levels of protein disulfide isomerase family A member 3 (PDIA3) augmented TGF-ß-mediated fibroblast activation. Inhibition of PDIA3 in vivo significantly reduced kidney fibrosis during ongoing renal injury and as such represented a new potential therapeutic pathway. Analysis of the signaling pathways of senescent epithelia connected senescence to organ fibrosis, permitting rational design of antifibrotic therapies.


Subject(s)
Cellular Senescence , Kidney , Mice , Humans , Animals , Cellular Senescence/physiology , Fibrosis , Kidney/pathology , Epithelium , Single-Cell Analysis
2.
JCI Insight ; 5(24)2020 12 17.
Article in English | MEDLINE | ID: mdl-33328386

ABSTRACT

Small noncoding RNAs, miRNAs (miRNAs), are emerging as important modulators in the pathogenesis of kidney disease, with potential as biomarkers of kidney disease onset, progression, or therapeutic efficacy. Bulk tissue small RNA-sequencing (sRNA-Seq) and microarrays are widely used to identify dysregulated miRNA expression but are limited by the lack of precision regarding the cellular origin of the miRNA. In this study, we performed cell-specific sRNA-Seq on tubular cells, endothelial cells, PDGFR-ß+ cells, and macrophages isolated from injured and repairing kidneys in the murine reversible unilateral ureteric obstruction model. We devised an unbiased bioinformatics pipeline to define the miRNA enrichment within these cell populations, constructing a miRNA catalog of injury and repair. Our analysis revealed that a significant proportion of cell-specific miRNAs in healthy animals were no longer specific following injury. We then applied this knowledge of the relative cell specificity of miRNAs to deconvolute bulk miRNA expression profiles in the renal cortex in murine models and human kidney disease. Finally, we used our data-driven approach to rationally select macrophage-enriched miR-16-5p and miR-18a-5p and demonstrate that they are promising urinary biomarkers of acute kidney injury in renal transplant recipients.


Subject(s)
Acute Kidney Injury/genetics , MicroRNAs/genetics , Organ Specificity/genetics , Animals , Biomarkers , Computational Biology/methods , Endothelial Cells/metabolism , Gene Expression Profiling/methods , High-Throughput Nucleotide Sequencing/methods , Kidney/metabolism , Kidney Tubules/metabolism , Macrophages/metabolism , Male , Mice , Mice, Inbred C57BL , MicroRNAs/metabolism
3.
J Am Soc Nephrol ; 31(12): 2833-2854, 2020 12.
Article in English | MEDLINE | ID: mdl-32978267

ABSTRACT

BACKGROUND: Little is known about the roles of myeloid cell subsets in kidney injury and in the limited ability of the organ to repair itself. Characterizing these cells based only on surface markers using flow cytometry might not provide a full phenotypic picture. Defining these cells at the single-cell, transcriptomic level could reveal myeloid heterogeneity in the progression and regression of kidney disease. METHODS: Integrated droplet- and plate-based single-cell RNA sequencing were used in the murine, reversible, unilateral ureteric obstruction model to dissect the transcriptomic landscape at the single-cell level during renal injury and the resolution of fibrosis. Paired blood exchange tracked the fate of monocytes recruited to the injured kidney. RESULTS: A single-cell atlas of the kidney generated using transcriptomics revealed marked changes in the proportion and gene expression of renal cell types during injury and repair. Conventional flow cytometry markers would not have identified the 12 myeloid cell subsets. Monocytes recruited to the kidney early after injury rapidly adopt a proinflammatory, profibrotic phenotype that expresses Arg1, before transitioning to become Ccr2+ macrophages that accumulate in late injury. Conversely, a novel Mmp12+ macrophage subset acts during repair. CONCLUSIONS: Complementary technologies identified novel myeloid subtypes, based on transcriptomics in single cells, that represent therapeutic targets to inhibit progression or promote regression of kidney disease.


Subject(s)
Kidney Diseases/etiology , Kidney Diseases/pathology , Myeloid Cells/physiology , Animals , Disease Models, Animal , Disease Progression , Kidney Diseases/metabolism , Macrophages/physiology , Male , Mice , Mice, Inbred C57BL , Sequence Analysis, RNA , Single-Cell Analysis , Ureteral Obstruction/etiology
4.
Hypertension ; 75(5): 1213-1222, 2020 05.
Article in English | MEDLINE | ID: mdl-32200679

ABSTRACT

GPR81 (G-protein-coupled receptor 81) is highly expressed in adipocytes, and activation by the endogenous ligand lactate inhibits lipolysis. GPR81 is also expressed in the heart, liver, and kidney, but roles in nonadipose tissues are poorly defined. GPR81 agonists, developed to improve blood lipid profile, might also provide insights into GPR81 physiology. Here, we assessed the blood pressure and renal hemodynamic responses to the GPR81 agonist, AZ'5538. In male wild-type mice, intravenous AZ'5538 infusion caused a rapid and sustained increase in systolic and diastolic blood pressure. Renal artery blood flow, intrarenal tissue perfusion, and glomerular filtration rate were all significantly reduced. AZ'5538 had no effect on blood pressure or renal hemodynamics in Gpr81-/- mice. Gpr81 mRNA was expressed in renal artery vascular smooth muscle, in the afferent arteriole, in glomerular and medullary perivascular cells, and in pericyte-like cells isolated from kidney. Intravenous AZ'5538 increased plasma ET-1 (endothelin 1), and pretreatment with BQ123 (endothelin-A receptor antagonist) prevented the pressor effects of GPR81 activation, whereas BQ788 (endothelin-B receptor antagonist) did not. Renal ischemia-reperfusion injury, which increases renal extracellular lactate, increased the renal expression of genes encoding ET-1, KIM-1 (Kidney Injury Molecule 1), collagen type 1-α1, TNF-α (tumor necrosis factor-α), and F4/80 in wild-type mice but not in Gpr81-/- mice. In summary, activation of GPR81 in vascular smooth muscle and perivascular cells regulates renal hemodynamics, mediated by release of the potent vasoconstrictor ET-1. This suggests that lactate may be a paracrine regulator of renal blood flow, particularly relevant when extracellular lactate is high as occurs during ischemic renal disease.


Subject(s)
Endothelin-1/physiology , Hemodynamics/drug effects , Receptors, G-Protein-Coupled/agonists , Animals , Arteries/drug effects , Blood Pressure/drug effects , Blood Pressure/physiology , Bosentan/pharmacology , Endothelin-1/blood , Glomerular Filtration Rate/drug effects , Heart/drug effects , Hemodynamics/physiology , Infusions, Intravenous , Kidney/blood supply , Kidney/drug effects , Lactates/blood , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/metabolism , Oligopeptides/pharmacology , Paracrine Communication , Peptides, Cyclic/pharmacology , Pericytes/drug effects , Pericytes/metabolism , Piperidines/pharmacology , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Receptors, G-Protein-Coupled/deficiency , Receptors, G-Protein-Coupled/genetics , Receptors, G-Protein-Coupled/physiology , Renal Circulation/drug effects , Renal Circulation/physiology , Reperfusion Injury/blood , Reperfusion Injury/drug therapy , Reperfusion Injury/genetics , Reperfusion Injury/physiopathology
5.
Methods Mol Biol ; 2067: 41-52, 2020.
Article in English | MEDLINE | ID: mdl-31701444

ABSTRACT

Traditional animal models mimic only the earliest stages of human diabetic nephropathy (DN), which limits their utility to dissect the pathogenesis of progressive disease or test novel therapeutics. In this chapter we describe in detail the experimental procedures required to conduct the Cyp1a1mRen2 rodent model, in which hyperglycemia and renin-dependent hypertension synergize to promote moderate proteinuria, renal fibrosis, and induction of many of the transcriptomic changes observed in the kidney of patients with progressive DN.


Subject(s)
Diabetes Mellitus, Experimental/complications , Diabetic Nephropathies/pathology , Hyperglycemia/complications , Hypertension/complications , Kidney/pathology , Animals , Cytochrome P-450 CYP1A1/genetics , Cytochrome P-450 Enzyme Inducers/pharmacology , Diabetes Mellitus, Experimental/chemically induced , Diabetic Nephropathies/etiology , Disease Progression , Fibrosis , Humans , Hyperglycemia/chemically induced , Hyperglycemia/genetics , Hypertension/genetics , Hypertension/metabolism , Indoles/pharmacology , Kidney/metabolism , Promoter Regions, Genetic/drug effects , Promoter Regions, Genetic/genetics , Rats , Rats, Transgenic , Renin/genetics , Renin/metabolism , Streptozocin/toxicity , Transcriptional Activation/drug effects
6.
Front Physiol ; 10: 1365, 2019.
Article in English | MEDLINE | ID: mdl-31803059

ABSTRACT

Chronic kidney disease (CKD) is prevalent worldwide and is associated with significant co-morbidities including cardiovascular disease (CVD). Traditionally, the subtotal nephrectomy (remnant kidney) experimental model has been performed in rats to model progressive renal disease. The model experimentally mimics CKD by reducing nephron number, resulting in renal insufficiency. Presently, there is a lack of translation of pre-clinical findings into successful clinical results. The pre-clinical nephrology field would benefit from reproducible progressive renal disease models in mice in order to avail of more widely available transgenics and experimental tools to dissect mechanisms of disease. Here we evaluate if a simplified single step subtotal nephrectomy (STNx) model performed in the 129S2/SV mouse can recapitulate the renal and cardiac changes observed in patients with CKD in a reproducible and robust way. The single step STNx surgery was well-tolerated and resulted in clinically relevant outcomes including hypertension, increased urinary albumin:creatinine ratio, and significantly increased serum creatinine, phosphate and urea. STNx mice developed significant left ventricular hypertrophy without reduced ejection fraction or cardiac fibrosis. Analysis of intra-renal inflammation revealed persistent recruitment of Ly6C hi monocytes transitioning to pro-fibrotic inflammatory macrophages in STNx kidneys. Unlike 129S2/SV mice, C57BL/6 mice exhibited renal fibrosis without proteinuria, renal dysfunction, or cardiac pathology. Therefore, the 129S2/SV genetic background is susceptible to induction of progressive proteinuric renal disease and cardiac hypertrophy using our refined, single-step flank STNx method. This reproducible model could be used to study the systemic pathophysiological changes induced by CKD in the kidney and the heart, intra-renal inflammation and for testing new therapies for CKD.

7.
Psychoneuroendocrinology ; 89: 13-22, 2018 03.
Article in English | MEDLINE | ID: mdl-29306773

ABSTRACT

Chronic exposure to stress during midlife associates with subsequent age-related cognitive decline and may increase the vulnerability to develop psychiatric conditions. Increased hypothalamic-pituitary-adrenal (HPA) axis activity has been implicated in pathogenesis though any causative role for glucocorticoids is unestablished. This study investigated the contribution of local glucocorticoid regeneration by the intracellular enzyme 11ß-hydroxysteroid dehydrogenase type 1 (11ß-HSD1), in persisting midlife stress-induced behavioral effects in mice. Middle-aged (10 months old) 11ß-HSD1-deficient mice and wild-type congenic controls were randomly assigned to 28 days of chronic unpredictable stress or left undisturbed (non-stressed). All mice underwent behavioral testing at the end of the stress/non-stress period and again 6-7 months later. Chronic stress impaired spatial memory in middle-aged wild-type mice. The effects, involving a wide spectrum of behavioral modalities, persisted for 6-7 months after cessation of stress into early senescence. Enduring effects after midlife stress included impaired spatial memory, enhanced contextual fear memory, impaired fear extinction, heightened anxiety, depressive-like behavior, as well as reduced hippocampal glucocorticoid receptor mRNA expression. In contrast, 11ß-HSD1 deficient mice resisted both immediate and enduring effects of chronic stress, despite similar stress-induced increases in systemic glucocorticoid activity during midlife stress. In conclusion, chronic stress in midlife exerts persisting effects leading to cognitive and affective dysfunction in old age via mechanisms that depend, at least in part, on brain glucocorticoids generated locally by 11ß-HSD1. This finding supports selective 11ß-HSD1 inhibition as a novel therapeutic target to ameliorate the long-term consequences of stress-related psychiatric disorders in midlife.


Subject(s)
11-beta-Hydroxysteroid Dehydrogenase Type 1/metabolism , Affect/physiology , Stress, Psychological/physiopathology , Animals , Corticosterone/metabolism , Fear/physiology , Glucocorticoids/metabolism , Hippocampus/metabolism , Hypothalamo-Hypophyseal System/metabolism , Male , Memory/physiology , Memory Disorders/metabolism , Mice , Mice, Inbred C57BL , Pituitary-Adrenal System/metabolism , Spatial Memory/physiology
8.
Endocr Connect ; 6(7): 446-457, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28720595

ABSTRACT

Chronic ACTH exposure is associated with adrenal hypertrophy and steroidogenesis. The underlying molecular processes in mice have been analysed by microarray, histological and immunohistochemical techniques. Synacthen infused for 2 weeks markedly increased adrenal mass and plasma corticosterone levels. Microarray analysis found greater than 2-fold changes in expression of 928 genes (P < 0.001; 397 up, 531 down). These clustered in pathways involved in signalling, sterol/lipid metabolism, cell proliferation/hypertrophy and apoptosis. Signalling genes included some implicated in adrenal adenomas but also upregulated genes associated with cyclic AMP and downregulated genes associated with aldosterone synthesis. Sterol metabolism genes were those promoting cholesterol supply (Scarb1, Sqle, Apoa1) and disposal (Cyp27a1, Cyp7b1). Oil red O staining showed lipid depletion consistent with reduced expression of genes involved in lipid synthesis. Genes involved in steroidogenesis (Star, Cyp11a1, Cyp11b1) were modestly affected (P < 0.05; <1.3-fold). Increased Ki67, Ccna2, Ccnb2 and Tk1 expression complemented immunohistochemical evidence of a 3-fold change in cell proliferation. Growth arrest genes, Cdkn1a and Cdkn1c, which are known to be active in hypertrophied cells, were increased >4-fold and cross-sectional area of fasciculata cells was 2-fold greater. In contrast, genes associated with apoptosis (eg Casp12, Clu,) were downregulated and apoptotic cells (Tunel staining) were fewer (P < 0.001) and more widely distributed throughout the cortex. In summary, long-term steroidogenesis with ACTH excess is sustained by genes controlling cholesterol supply and adrenal mass. ACTH effects on adrenal morphology and genes controlling cell hypertrophy, proliferation and apoptosis suggest the involvement of different cell types and separate molecular pathways.

9.
Kidney Int ; 89(5): 1125-1135, 2016 May.
Article in English | MEDLINE | ID: mdl-27083286

ABSTRACT

Many diabetic patients suffer from declining renal function without developing albuminuria. To identify alternative biomarkers for diabetic nephropathy (DN) we performed urinary peptidomic analysis in a rodent model in which hyperglycemia and hypertension synergize to promote renal pathologic changes consistent with human DN. We identified 297 increased and 15 decreased peptides in the urine of rats with DN compared with controls, including peptides derived from proteins associated with DN and novel candidate biomarkers. We confirmed by ELISA that one of the parent proteins, urinary epidermal growth factor (uEGF), was more than 2-fold reduced in rats with DN in comparison with controls. To assess the clinical utility of uEGF we examined renal outcomes in 642 participants from the Edinburgh Type 2 Diabetes Study who were normoalbuminuric and had preserved renal function at baseline. After adjustment for established renal risk factors, a lower uEGF to creatinine ratio was associated with new-onset estimated glomerular filtration rate less than 60 ml/min per 1.73m(2) (odds ratio 0.48; 95% confidence interval, 0.26-0.90), rapid (over 5% per annum) decline in renal function (odds ratio 0.44; 95% confidence interval, 0.27-0.72) or the composite of both outcomes (odds ratio 0.38; 95% confidence interval, 0.24-0.62). Thus, the utility of a low uEGF to creatinine ratio as a biomarker of progressive decline in renal function in normoalbuminuric patients should be assessed in additional populations.


Subject(s)
Diabetes Mellitus, Type 2/complications , Diabetic Nephropathies/urine , ErbB Receptors/urine , Proteinuria/urine , Proteomics , Receptor, ErbB-2/urine , Aged , Animals , Biomarkers/urine , Case-Control Studies , Chi-Square Distribution , Creatinine/urine , Diabetes Mellitus, Type 2/diagnosis , Diabetic Nephropathies/diagnosis , Diabetic Nephropathies/etiology , Diabetic Nephropathies/physiopathology , Disease Models, Animal , Disease Progression , Enzyme-Linked Immunosorbent Assay , Female , Glomerular Filtration Rate , Humans , Hypertension/complications , Kaplan-Meier Estimate , Kidney/physiopathology , Logistic Models , Male , Mass Spectrometry , Middle Aged , Multivariate Analysis , Odds Ratio , Predictive Value of Tests , Proteomics/methods , Rats, Transgenic , Risk Factors , Scotland , Urinalysis
10.
PLoS One ; 8(10): e78209, 2013.
Article in English | MEDLINE | ID: mdl-24205160

ABSTRACT

Amelioration of rodent type 2 diabetes by hemin has been linked to increased heme oxygenase (HO) activity, however alternative mechanisms have recently been proposed for its anti-diabetic effect. We sought to determine the anti-diabetic efficacy of heme arginate (HA), a clinically licensed preparation of heme, and whether its predominant mode of action is via increased HO activity. Intravenous administration of HA reduced hyperglycemia in diabetic (db/db) mice. Co-administration of the HO inhibitor stannous (IV) mesoporphyrin IX dichloride (SM) resulted unexpectedly in a further improvement in glycaemic control despite restoring HO activity to baseline levels. The anti-diabetic effects of HA±SM were associated with increased adiposity, increased serum adiponectin levels, reduced adipose tissue and islet inflammation and preservation of islet ß-cell function. HO activity independent effects of HA on adipogenesis and ß-cell inflammation were further confirmed in cell culture models using the 3T3-L1 pre-adipocyte and MIN6 ß-cell lines, respectively. In conclusion, our work demonstrates that the heme component of HA ameliorates experimental type 2 diabetes by promoting metabolically favourable adipogenesis and preserving islet ß-cell function, but this is not mediated via increased HO activity.


Subject(s)
Arginine/administration & dosage , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Type 2/drug therapy , Heme Oxygenase (Decyclizing)/metabolism , Heme/administration & dosage , 3T3 Cells , Adipocytes/drug effects , Adipocytes/metabolism , Adipogenesis/drug effects , Adiponectin/blood , Adiponectin/metabolism , Adipose Tissue/drug effects , Adipose Tissue/metabolism , Adiposity/drug effects , Animals , Blood Glucose/drug effects , Cell Line , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/metabolism , Hyperglycemia/blood , Hyperglycemia/drug therapy , Hyperglycemia/metabolism , Inflammation/blood , Inflammation/drug therapy , Inflammation/metabolism , Insulin-Secreting Cells/drug effects , Insulin-Secreting Cells/metabolism , Metalloporphyrins/administration & dosage , Mice , Pilot Projects
SELECTION OF CITATIONS
SEARCH DETAIL